UB Paderborn / Katalog / Suche / in CDI

Long-term follow-up of a trial comparing post-remission treatment with autologous or allogeneic bone marrow transplantation or intensive chemotherapy in younger acute myeloid leukemia patients

Haematologica (Roma), 2020-01, Vol.105 (1), p.e13

2020

Volltextzugriff (PDF)

The COVID‐19 pandemic and management of GIMEMA clinical trials: changes and challenges

British journal of haematology, 2020-08, Vol.190 (4), p.e211-e214

2020

Volltextzugriff (PDF)

The level of patient-reported outcome reporting in randomised controlled trials of brain tumour patients: A systematic review

European journal of cancer (1990), 2014-09, Vol.50 (14), p.2432-2448

2014

Volltextzugriff (PDF)

Temsirolimus, an mTOR inhibitor, in combination with lower-dose clofarabine as salvage therapy for older patients with acute myeloid leukaemia: results of a phase II GIMEMA study (AML-1107)

British journal of haematology, 2012-01, Vol.156 (2), p.205-212

2012

Volltextzugriff (PDF)

S136: ANALYSIS OF FACTORS ASSOCIATED WITH LONG‐TERM SURVIVAL IN A LARGE ACUTE PROMYELOCYTIC LEUKEMIA (APL) PATIENT COHORT: A HARMONY ALLIANCE STUDY

HemaSphere, 2023-08, Vol.7 (S3), p.e53745c4-n/a

2023

Volltextzugriff (PDF)

P495: UNLOCKING THE POTENTIAL OF SYNTHETIC PATIENTS FOR ACCELERATING CLINICAL TRIALS: RESULTS OF THE FIRST GIMEMA EXPERIENCE

HemaSphere, 2023-08, Vol.7 (S3), p.e4536536-n/a

2023

Volltextzugriff (PDF)

Unlocking the potential of synthetic patients for accelerating clinical trials: Results of the first GIMEMA experience on acute myeloid leukemia patients

EJHaem, 2024-04, Vol.5 (2), p.353-359

2024

Volltextzugriff (PDF)

Physicians' Perceptions of Clinical Utility of a Digital Health Tool for Electronic Patient-Reported Outcome Monitoring in Real-Life Hematology Practice. Evidence From the GIMEMA-ALLIANCE Platform

Frontiers in oncology, 2022-03, Vol.12, p.826040-826040

2022

Volltextzugriff (PDF)

Clinician-reported symptomatic adverse events in cancer trials: are they concordant with patient-reported outcomes?

Journal of comparative effectiveness research, 2019-04, Vol.8 (5), p.279-288

2019

Volltextzugriff (PDF)

Sonographic biometry of liver and spleen size long after closure of abdominal wall defects

European journal of pediatrics, 2003-07, Vol.162 (7-8), p.490-492

2003

Volltextzugriff (PDF)

Robust Validation of the UKALL High Hyperdiploid Risk Profile Using Individual Patient Data Collected By the Harmony Alliance

Blood, 2022-11, Vol.140 (Supplement 1), p.6369-6370

2022

Volltextzugriff (PDF)

Real-world evaluation of UK high hyperdiploidy profile using a large cohort of patients provided by HARMONY data platform

Leukemia, 2023-12, Vol.37 (12), p.2493-2496

2023

Volltextzugriff (PDF)

Gimema AML1718 Part 1: Planned Interim Analysis of a Safety Run-in and Phase 2 Open-Label Study of Venetoclax, Fludarabine, Idarubicin and Cytarabine (V-FLAI) in the Induction Therapy of Non Low-Risk Acute Myeloid Leukemia

Blood, 2022-11, Vol.140 (Supplement 1), p.1705-1707

2022

Volltextzugriff (PDF)

Clinical Utility and Physician Perceptions of a Digital Platform for Electronic Patient-Reported Outcomes Monitoring in Patients with Hematologic Malignancies in Real-World Practice

Blood, 2021-11, Vol.138 (Supplement 1), p.4017-4017

2021

Volltextzugriff (PDF)

Seeing Their Children in Pain: Symptoms of Posttraumatic Stress Disorder in Mothers of Children with an Anomaly Requiring Surgery at Birth

American journal of perinatology, 2016-07, Vol.33 (8), p.770

2016

Volltextzugriff (PDF)

Long-term bladder function followup in boys with posterior urethral valves: comparison of noninvasive vs invasive urodynamic studies

The Journal of urology, 2012-09, Vol.188 (3), p.953

2012

Volltextzugriff (PDF)

Risk-adapted MRD-directed therapy for young adults with acute myeloid leukemia: 6-year update of the GIMEMA AML1310 trial

Blood advances, 2024-08, Vol.8 (16), p.4410-4413

2024

Volltextzugriff (PDF)

RISK-ADAPTED MRD-DIRECTED THERAPY FOR YOUNG ACUTE MYELOID LEUKEMIA ADULTS: 6-YEAR UPDATE OF THE GIMEMA AML1310 TRIAL

Blood advances, 2024-07

2024

Volltextzugriff (PDF)

Follow-up of anorectal anomalies: the Italian parents' and patients' perspective

Journal of pediatric surgery, 2006-04, Vol.41 (4), p.837-841

2006

Volltextzugriff (PDF)

Is endoscopic follow-up needed in pediatric patients who undergo surgery for GERD?

Gastrointestinal endoscopy, 2002-03, Vol.55 (3), p.387-389

2002

Volltextzugriff (PDF)

Menü

Weitere Dienste

Einstellungen

Long-term follow-up of a trial comparing post-remission treatment with autologous or allogeneic bone marrow transplantation or intensive chemotherapy in younger acute myeloid leukemia patients

GIMEMA AML1310 trial of risk-adapted, MRD-directed therapy for young adults with newly diagnosed acute myeloid leukemia

The COVID‐19 pandemic and management of GIMEMA clinical trials: changes and challenges

The level of patient-reported outcome reporting in randomised controlled trials of brain tumour patients: A systematic review

Temsirolimus, an mTOR inhibitor, in combination with lower-dose clofarabine as salvage therapy for older patients with acute myeloid leukaemia: results of a phase II GIMEMA study (AML-1107)

S136: ANALYSIS OF FACTORS ASSOCIATED WITH LONG‐TERM SURVIVAL IN A LARGE ACUTE PROMYELOCYTIC LEUKEMIA (APL) PATIENT COHORT: A HARMONY ALLIANCE STUDY

P495: UNLOCKING THE POTENTIAL OF SYNTHETIC PATIENTS FOR ACCELERATING CLINICAL TRIALS: RESULTS OF THE FIRST GIMEMA EXPERIENCE

Unlocking the potential of synthetic patients for accelerating clinical trials: Results of the first GIMEMA experience on acute myeloid leukemia patients

Physicians' Perceptions of Clinical Utility of a Digital Health Tool for Electronic Patient-Reported Outcome Monitoring in Real-Life Hematology Practice. Evidence From the GIMEMA-ALLIANCE Platform

Clinician-reported symptomatic adverse events in cancer trials: are they concordant with patient-reported outcomes?

Sonographic biometry of liver and spleen size long after closure of abdominal wall defects

Robust Validation of the UKALL High Hyperdiploid Risk Profile Using Individual Patient Data Collected By the Harmony Alliance

Real-world evaluation of UK high hyperdiploidy profile using a large cohort of patients provided by HARMONY data platform

Gimema AML1718 Part 1: Planned Interim Analysis of a Safety Run-in and Phase 2 Open-Label Study of Venetoclax, Fludarabine, Idarubicin and Cytarabine (V-FLAI) in the Induction Therapy of Non Low-Risk Acute Myeloid Leukemia

Clinical Utility and Physician Perceptions of a Digital Platform for Electronic Patient-Reported Outcomes Monitoring in Patients with Hematologic Malignancies in Real-World Practice

Seeing Their Children in Pain: Symptoms of Posttraumatic Stress Disorder in Mothers of Children with an Anomaly Requiring Surgery at Birth

Impact of the type of anthracycline and of stem cell transplantation in younger patients with acute myeloid leukaemia: Long‐term follow up of a phase III study

Long-term bladder function followup in boys with posterior urethral valves: comparison of noninvasive vs invasive urodynamic studies

Risk-adapted MRD-directed therapy for young adults with acute myeloid leukemia: 6-year update of the GIMEMA AML1310 trial

Impact of the Type of Anthracycline and of Allogeneic Stem Cell Transplantation in the Treatment of Younger Acute Myeloid Leukemia Patients: Long-Term Follow-up of the EORTC-Gimema AML-10 Trial

RISK-ADAPTED MRD-DIRECTED THERAPY FOR YOUNG ACUTE MYELOID LEUKEMIA ADULTS: 6-YEAR UPDATE OF THE GIMEMA AML1310 TRIAL

Post-Remission Treatment with Autologous or Allogeneic Bone Marrow Transplantation or Intensive Chemotherapy in Younger AML Patients: Long-Term Follow-up Results of the EORTC/Gimema AML-8A Study

Follow-up of anorectal anomalies: the Italian parents' and patients' perspective

Temsirolimus, An mTOR Inhibitor, In Combination with Low-Dose Clofarabine in Older Patients with Advanced Acute Myeloid Leukemia: Results of a Phase 2 GIMEMA Study (AML-1107)

Is endoscopic follow-up needed in pediatric patients who undergo surgery for GERD?

Suchergebnisse filtern